pathogen reduced SARS-CoV-2 convalescent plasma
/ Vanderbilt University Medical Center
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
November 04, 2021
PassItOn II: Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
(clinicaltrials.gov)
- P3; N=974; Completed; Sponsor: Vanderbilt University Medical Center; Recruiting ➔ Completed
Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 23, 2021
PassItOn II: Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
(clinicaltrials.gov)
- P3; N=1000; Recruiting; Sponsor: Vanderbilt University Medical Center; Trial completion date: Apr 2021 ➔ Jul 2021
Clinical • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
November 10, 2020
PassItOn II: Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
(clinicaltrials.gov)
- P3; N=1000; Recruiting; Sponsor: Vanderbilt University Medical Center; N=500 ➔ 1000
Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 04, 2020
PassItOn II: Passive Immunity Trial of Nashville II for COVID-19
(clinicaltrials.gov)
- P3; N=500; Recruiting; Sponsor: Vanderbilt University Medical Center; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
April 24, 2020
PassItOn II: Passive Immunity Trial of Nashville II
(clinicaltrials.gov)
- P3; N=500; Not yet recruiting; Sponsor: Vanderbilt University Medical Center
Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease
1 to 5
Of
5
Go to page
1